ATE538809T1 - Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff - Google Patents

Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Info

Publication number
ATE538809T1
ATE538809T1 AT04746847T AT04746847T ATE538809T1 AT E538809 T1 ATE538809 T1 AT E538809T1 AT 04746847 T AT04746847 T AT 04746847T AT 04746847 T AT04746847 T AT 04746847T AT E538809 T1 ATE538809 T1 AT E538809T1
Authority
AT
Austria
Prior art keywords
vaccine
selecting appropriate
biological sample
precursor cells
highly responsive
Prior art date
Application number
AT04746847T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE538809T1 publication Critical patent/ATE538809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT04746847T 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff ATE538809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (ja) 2003-06-27 2004-06-25 Ｗｔ１ワクチン適応患者の選択方法

Publications (1)

Publication Number Publication Date
ATE538809T1 true ATE538809T1 (de) 2012-01-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04746847T ATE538809T1 (de) 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Country Status (9)

Country Link
US (1) US10500257B2 (de)
EP (3) EP2343083B1 (de)
JP (1) JP4566912B2 (de)
KR (2) KR101292971B1 (de)
CN (1) CN1842603B (de)
AT (1) ATE538809T1 (de)
CA (2) CA2530184C (de)
ES (3) ES2378156T3 (de)
WO (1) WO2005001117A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337743C (en) * 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP2343083B1 (de) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Verfahren zum Diagnostizieren von Krebs, umfassend die Messung von WT1-spezifischen CTL-Vorläuferzellen
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
DK2186896T3 (en) * 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
CA2593714C (en) * 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) * 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
EP2010209B1 (de) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
EP2392675A1 (de) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IFNG
MY158219A (en) 2007-02-27 2016-09-15 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
EP2116596A4 (de) 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc Krebs-antigen-spezifisches t-zellen-rezeptorgen, durch das gen kodiertes peptid und deren anwendung
TWI504407B (zh) 2007-12-05 2015-10-21 Int Inst Cancer Immunology Inc 癌疫苗組合物
MX361299B (es) 2010-10-05 2018-11-30 Otsuka Pharmaceutical Co Ltd Star Metodo para activar celulas auxiliares.
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
EP2561759A1 (de) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum
US10301257B2 (en) 2011-09-16 2019-05-28 Bayer Intellectual Property Gmbh Use of acylsulfonamides for improving plant yield
AU2012307322B2 (en) 2011-09-16 2016-07-14 Bayer Intellectual Property Gmbh Use of 5-phenyl- or 5-benzyl-2 isoxazoline-3 carboxylates for improving plant yield
CN103781352A (zh) 2011-09-16 2014-05-07 拜耳知识产权有限责任公司 苯基吡唑啉-3-甲酸酯类用于提高植物产量的用途
EP3520810A3 (de) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogene wt-1-peptide und verwendung davon
EP2911683B1 (de) 2012-10-23 2019-09-25 Ubivac, LLC Mit allogenen autophagosomen angereicherte zusammensetzung zur behandlung von krankheiten
BR112015013697A2 (pt) 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar
PL2945647T3 (pl) * 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN105188375B (zh) 2013-03-05 2018-04-06 拜耳作物科学股份公司 喹啉衍生物用于增加植物产量的用途
HUE045111T2 (hu) 2013-03-05 2019-12-30 Bayer Cropscience Ag N-(2-metoxibenzil)-4-[(metilaminokarbonil)amino]benzolszulfonamid inszekticidekkel vagy fungicidekkel képzett kombinációjának alkalmazása növénytermesztés hatásfokának növelésére
US10001491B2 (en) * 2013-03-28 2018-06-19 Centre Hospitalier Universitaire De Montpellier Method for determining radiosensitivity
ES2954899T3 (es) 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedimiento para predecir el efecto clínico de una inmunoterapia
RS63561B1 (sr) 2015-11-20 2022-10-31 Memorial Sloan Kettering Cancer Center Kompozicija za lečenje raka
EP3318135A1 (de) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Sprudelndes süssigkeitenmaterial, verfahren zu dessen herstellung und daraus hergestellte produkte
MA51302A (fr) 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
MX2022014249A (es) * 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
CA2116526A1 (en) 1991-08-28 1993-03-18 William V. Williams T cell receptor-based therapy for rheumatoid arthritis
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
ES2242221T3 (es) 1996-04-16 2005-11-01 Kishimoto, Tadamitsu Procedimiento para la deteccion de celulas de cancer solido y de heterotipia histologica y procedimiento para el examen de tejidos destinados a trasplantes de medula osea y al trasplante de celulas madre sanguineas perifericas.
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
BR9914116A (pt) 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
KR100479648B1 (ko) 1999-02-23 2005-03-30 베일러 칼리지 오브 메디신 Ｔ 세포 수용체 Ｖβ-Ｄβ-Ｊβ서열 및 그 검출방법
WO2001094944A2 (en) * 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US20060035291A1 (en) 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
EP1447092A4 (de) 2001-09-28 2007-07-11 Haruo Sugiyama Neues verfahren zur induktion von antigenspezifischen t-zellen
WO2003059155A2 (en) 2002-01-09 2003-07-24 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
JP4365784B2 (ja) * 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
EP2343083B1 (de) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Verfahren zum Diagnostizieren von Krebs, umfassend die Messung von WT1-spezifischen CTL-Vorläuferzellen
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
WO2005053603A2 (en) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Antigen receptor variable region typing
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
EP2116596A4 (de) 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc Krebs-antigen-spezifisches t-zellen-rezeptorgen, durch das gen kodiertes peptid und deren anwendung
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因

Also Published As

Publication number Publication date
JPWO2005001117A1 (ja) 2006-08-10
ES2478446T3 (es) 2014-07-22
KR20060069363A (ko) 2006-06-21
EP1640458A1 (de) 2006-03-29
EP1640458A4 (de) 2008-05-21
US20070128207A1 (en) 2007-06-07
HK1090093A1 (en) 2006-12-15
EP2343083A2 (de) 2011-07-13
EP2338509A2 (de) 2011-06-29
US10500257B2 (en) 2019-12-10
KR101292971B1 (ko) 2013-08-12
ES2378156T3 (es) 2012-04-09
JP4566912B2 (ja) 2010-10-20
WO2005001117A1 (ja) 2005-01-06
KR101431312B1 (ko) 2014-08-20
CA2893995A1 (en) 2005-01-06
EP1640458B1 (de) 2011-12-28
EP2338509A3 (de) 2011-11-30
CA2530184C (en) 2015-10-06
KR20110049877A (ko) 2011-05-12
CN1842603A (zh) 2006-10-04
EP2343083B1 (de) 2014-01-15
CA2530184A1 (en) 2005-01-06
EP2338509B1 (de) 2014-06-18
ES2443582T3 (es) 2014-02-19
EP2343083A3 (de) 2011-08-03
CN1842603B (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
DE60327354D1 (de) Diagnostischer assay zur bestimmung einer zellvermittelten immunantwort
ATE399323T1 (de) Verfahren zur bestimmung von amyloidogenen proteinen
ATE520979T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
MX342791B (es) Ensayo elisa para la detección de vegf.
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
Lu et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS
ATE184703T1 (de) Verfahren und testsatz zur messung von endogenen zytokinen
TW200626900A (en) Wnt proteins and detection and treatment of cancer
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
ATE314648T1 (de) Diagnostisches verfahren für asthma
DE10391021D2 (de) Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
ATE420115T1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
Cummins et al. Raman spectroscopy of fingernails: A novel tool for evaluation of bone quality?
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
ATE547534T1 (de) Verfahren zur nichtinvasiven untersuchung nicht- alkoholischer steatohepatitis mittels quantifizierung von cytochrom-c
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers